Condition: Hormone Receptor-Positive Breast Cancer · HER2-Negative Breast Cancer · Sponsor: Rutgers, The State University of New Jersey
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).
This description comes directly from the study's public registry record.
Coral Omene, MD., PhD · 732-235-3374 · co273@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| Trinitas Comprehensive Cancer Center | Elizabeth, New Jersey, United States | Recruiting |
| RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton, New Jersey, United States | Not Yet Recruiting |
| RWJBarnabas Health - Cooperman Barnabas, Livingston | Livingston, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Monmouth Medical Center | Long Branch, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Newark Beth Israel Medical Center | Newark, New Jersey, United States | Recruiting |
| RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset | Somerville, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06518837